Ajanta Pharma signs pact with Biocon for marketing Semaglutide in 26 countries, stock surges 6%Ajanta Pharma signs pact with Biocon for marketing Semaglutide in 26 countries, stock surges 6%

Introduction

leading specialty pharmaceutical company entered an in-licensing agreement for Semaglutide to market the diabetes therapy across Africa, the Middle East, and Central Asia after regulatory approvals.

Also Read: Royal India Corp shares rise 9% on signing MoU with JSC ETC GET

Share price movement of Ajanta Pharma

On December 24, 2025, Ajanta Pharma Ltd opened at ₹2,736.20, up 2.62% from its previous close of ₹2,666.45. The stock touched a high of ₹2,820.00 (5.76%) and a low of ₹2,736.20 (2.62%). By 1:31 PM, it traded at ₹2,748.10, a 3.06% increase, with a market cap of ₹34,333.56 crore.

Ajanta Pharma Signs Semaglutide Deal

Ajanta Pharma Ltd announced an in-licensing agreement with Biocon Ltd for Semaglutide. Biocon will supply the product for exclusive and semi-exclusive marketing across 26 countries.

The agreement covers 23 countries with exclusive rights and three countries with semi-exclusive rights across Africa, the Middle East and Central Asia. Semaglutide is a GLP-1 receptor agonist.

Product patents expire in most markets by March 2026. Ajanta plans commercialization after regulatory approvals expected in late 2026 or early 2027 across the covered regions.

Stock performance of Ajanta Pharma for Period of 1 week, 6 months, and 1 year

Ajanta Pharma Ltd delivered a 2.61% return over the past week. The stock rose 5.85% over the past six months. It declined 4.84% over the past year.

Also Read: HCLtech arm to acquire Jaspersoft from Cloud Software Group

Shareholding pattern of Ajanta Pharma

Particulars	Sep 2025	Jun 2025	Mar 2025
Promoter	66.30%	66.30%	66.30%
FII	8.50%	8.90%	8.90%
DII	17.90%	17.50%	17.50%
Public	7.30%	7.40%	7.40%

About Ajanta Pharma

Ajanta Pharma Ltd (NSE: AJANTPHARM) is a specialty pharmaceutical company focused on branded generics across India, Asia, and Africa, with presence in the US, strong R&D capabilities, and multiple manufacturing facilities in India.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs